In vivo Hybridoma Approach to Identify Novel Therapeutic- and Diagnostic-Grade Antibodies

The Curia hybridoma platform offers a variety of high-performance hybridoma technologies to discover great antibodies. The specific discovery approach depends on project-intrinsic parameters. These comprise practical (client resource, timeline) and scientific considerations. For the latter, we perform a rigorous upfront target analysis to devise the best discovery approach.  Here we use bioinformatics, literature, and patent data to identify target-specific considerations that could impact our discovery efforts. This due diligence helps ensure that we are following an optimal path for antibody discovery from the outset.

View our latest hydrodynamic gene transfer (HDT) publications related to DNA-based immunization:

Robust Expansion of Dendritic Cells in vivo by Hydrodynamic FLT3L-FC Gene Transfer

A Chimeric Antibody Against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models

Hybridoma Discovery Workflow at Curia

Other differentiators:

• Multiple immunization strategies (protein, DNA, cell-based immunogens) using a variety of WT strains and/or human-antibody producing transgenics and/or target-specific KOs coupled with in-life plasma titer checks allows us to track antibody responses in vivo and focus on the most promising animals for subsequent fusion and antibody recovery.
• Expertise in innovative tolerance-breaking approaches for targets with high human-mouse identity or if human/mouse target cross-reactivity is required.
• 384-well screening format enables high capacity enables interrogation of 4,000-12,000 hybridomas in a standard campaign.
• Intellicyt® iQue Screeners enable high-throughput multiplex flow cytometry-based primary screening to immediately identify hits with desired specificity and cross-reactivity requirements.
• Functional assay development and integration into screening cascade
• Seamless integration with Curia’s complete range of analytic and production capabilities (immunogen production, cell line generation, hybridoma sequencing, purified antibody production, affinity measurements by Carterra® (SPR) and Octet®, recombinant production at any desired scale, humanization/affinity maturation if needed)

Immunization Comparisons